|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 2429 |
FusionGeneSummary for ARHGAP29_MID2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ARHGAP29_MID2 | Fusion gene ID: 2429 | Hgene | Tgene | Gene symbol | ARHGAP29 | MID2 | Gene ID | 9411 | 11043 |
| Gene name | Rho GTPase activating protein 29 | midline 2 | |
| Synonyms | PARG1 | FXY2|MRX101|RNF60|TRIM1 | |
| Cytomap | 1p22.1 | Xq22.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | rho GTPase-activating protein 29PTPL1-associated RhoGAP 1 (PARG1)PTPL1-associated RhoGAP protein 1rho-type GTPase-activating protein 29 | probable E3 ubiquitin-protein ligase MID2RING finger protein 60RING-type E3 ubiquitin transferase MID2midin 2midline defect 2tripartite motif protein 1tripartite motif-containing protein 1 | |
| Modification date | 20180519 | 20180519 | |
| UniProtAcc | Q52LW3 | Q9UJV3 | |
| Ensembl transtripts involved in fusion gene | ENST00000260526, ENST00000482481, ENST00000370217, | ENST00000262843, ENST00000443968, | |
| Fusion gene scores | * DoF score | 4 X 3 X 3=36 | 3 X 4 X 5=60 |
| # samples | 4 | 5 | |
| ** MAII score | log2(4/36*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(5/60*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ARHGAP29 [Title/Abstract] AND MID2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | MID2 | GO:0032897 | negative regulation of viral transcription | 18248090 |
| Tgene | MID2 | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 23077300 |
| Tgene | MID2 | GO:0045087 | innate immune response | 18248090 |
| Tgene | MID2 | GO:0046597 | negative regulation of viral entry into host cell | 18248090 |
| Tgene | MID2 | GO:1902187 | negative regulation of viral release from host cell | 18248090 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | BLCA | TCGA-GV-A3QH-01A | ARHGAP29 | chr1 | 94702971 | - | MID2 | chrX | 107147188 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5UTR-3CDS | ENST00000260526 | ENST00000262843 | ARHGAP29 | chr1 | 94702971 | - | MID2 | chrX | 107147188 | + |
| 5UTR-3CDS | ENST00000260526 | ENST00000443968 | ARHGAP29 | chr1 | 94702971 | - | MID2 | chrX | 107147188 | + |
| intron-3CDS | ENST00000482481 | ENST00000262843 | ARHGAP29 | chr1 | 94702971 | - | MID2 | chrX | 107147188 | + |
| intron-3CDS | ENST00000482481 | ENST00000443968 | ARHGAP29 | chr1 | 94702971 | - | MID2 | chrX | 107147188 | + |
| 5UTR-3CDS | ENST00000370217 | ENST00000262843 | ARHGAP29 | chr1 | 94702971 | - | MID2 | chrX | 107147188 | + |
| 5UTR-3CDS | ENST00000370217 | ENST00000443968 | ARHGAP29 | chr1 | 94702971 | - | MID2 | chrX | 107147188 | + |
Top |
FusionProtFeatures for ARHGAP29_MID2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ARHGAP29 | MID2 |
| GTPase activator for the Rho-type GTPases by convertingthem to an inactive GDP-bound state. Has strong activity towardRHOA, and weaker activity toward RAC1 and CDC42. May act as aspecific effector of RAP2A to regulate Rho. In concert withRASIP1, suppresses RhoA signaling and dampens ROCK and MYH9activities in endothelial cells and plays an essential role inblood vessel tubulogenesis. {ECO:0000269|PubMed:15752761,ECO:0000269|PubMed:9305890}. | May play a role in microtubule stabilization.{ECO:0000303|PubMed:24115387}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ARHGAP29_MID2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for ARHGAP29_MID2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| ARHGAP29 | MAGEA11, PTPN13, SIRT1, KDM1A, GPR183, HERC1, CEP128, XPO1, CDH1, EGFR, JPH4 | MID2 | DYDC1, MID2, MID1, TRIM29, TRIM32, IGBP1, UBE2D4, UBE2N, UBE2U, UBE2D1, UBE2D2, UBE2D3, UBE2E1, UBE2E2, UBE2E3, GFI1B, DGCR6, KIF1A, MVP, SLC25A6, AQP1, BYSL, RUNX1T1, CHD2, CTSZ, DCX, GOLGA2, HOXB9, KIFC3, LGALS8, MFAP1, MOS, PSMA1, TRIM27, SDCBP, SNAI1, TCEA2, TCEB3, ZNF24, ZNF165, STX11, TOP3B, RPH3AL, ZSCAN12, ZBTB24, JOSD1, NR1D2, CALCOCO2, SPRY2, NXF1, FARS2, FAM107A, ISCU, GORASP2, PRPF31, DIEXF, SPG21, WT1-AS, SYT17, ADAMTSL4, CCHCR1, MAGOHB, FAM90A1, C19orf66, TRPV6, RCOR3, UNC45A, FAM214A, LGALS14, TRIM54, CBX8, ZNF250, DMRT3, MID1IP1, GMCL1, METTL17, AEN, OTUB2, SCNM1, ZFYVE21, LENG1, ZC2HC1C, PTCD2, UBTD1, FBXL18, TSGA10, KIAA1683, THAP7, ATRIP, FAM161A, UTP23, BRMS1L, ZGPAT, ZNF587, FBF1, DGCR6L, CCDC120, SNAP47, FRMD6, ZNF440, ZNF792, RPP25L, ZNF785, CCDC42, ZNF417, SLC25A48, ZNF564, PPP1R18, SPATA24, BCL6B, CEP57L1, TRIM42, BRCA1, UBXN1, EPN3, COX5B, ZNF774, TMEM14B, FAM115A, HIF1A, CDKN2AIP, SPAG5, TUBB, TUBA1B, TUBB4B, CEP128, ASPM, PSMD3, PSMC2, PSMD11, PSMD2, PSMB5, GMNN |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ARHGAP29_MID2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for ARHGAP29_MID2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ARHGAP29 | C0334634 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | 1 | CTD_human |
| Tgene | MID2 | C3890168 | MENTAL RETARDATION, X-LINKED 101 | 1 | UNIPROT |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|